14-3-3ζ, a novel androgen-responsive gene, is upregulated in prostate cancer and promotes prostate cancer cell proliferation and survival

Clinical Cancer Research

Volumn 18, Issue 20, 2012, Pages 5617-5627

  Murata, Taro ^a   Takayama, Ken Ichi ^a,c   Urano, Tomohiko ^a,c   Fujimura, Tetsuya ^a   Ashikari, Daisaku ^a,b   Obinata, Daisuke ^a,b   Horie Inoue, Kuniko ^c   Takahashi, Satoru ^b   Ouchi, Yasuyoshi ^a   Homma, Yukio ^a   Inoue, Satoshi ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

14 3 3 ZETA PROTEIN; ANDROGEN RECEPTOR; ETOPOSIDE; MESSENGER RNA; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

14 3 3 ZETA GENE; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CLINICAL FEATURE; CONTROLLED STUDY; DNA MICROARRAY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MOLECULAR PATHOLOGY; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE EXPRESSION; UPREGULATION; WESTERN BLOTTING;

14-3-3 PROTEINS; ANDROGENS; APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84867497510     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0281     Document Type: Article

References (56)

1. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 1997;94:3320-23. (Pubitemid 27157309)
2. Hsing AW, Reichardt JK, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002;52:213-35. (Pubitemid 34791223)
3. Debes JD, Tindall DJ. The role of androgens and the androgen receptor in prostate cancer. Cancer Lett 2002;187:1-7. (Pubitemid 35279326)
4. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765-71. (Pubitemid 38120921)
5. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7. (Pubitemid 41557182)
6. Cawley S, Bekiranov S, Ng HH, Kapranov P, Sekinger EA, Kampa D, et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 2004;116:499-509. (Pubitemid 38264428)
7. Bernstein BE, Kamal M, Lindblad-Toh K, Bekiranov S, Bailey DK, Huebert DJ, et al. Genomic maps and comparative analysis of histone modi fications in human and mouse. Cell 2005;120:169-81. (Pubitemid 40174761)
8. Takayama K, Kaneshiro K, Tsutsumi S, Horie-Inoue K, Ikeda K, Urano T, et al. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 2007;26:4453-63. (Pubitemid 47014467)
9. Takayama K, Tsutsumi S, Suzuki T, Horie-Inoue K, Ikeda K, Kaneshiro K, et al. Amyloid precursor protein is a primary androgen target gene that promotes prostate cancer growth. Cancer Res 2009;69:137-42.
10. Takayama K, Tsutsumi S, Katayama S, Okayama T, Horie-Inoue K, Ikeda K, et al. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genomewide androgen receptor signaling in prostate cancer cells. Oncogene 2011;30:619- 30.
11. Aitken A. 14-3-3 proteins on the MAP. Trends Biochem Sci 1995;20:95-97.
12. Aitken A. 14-3-3 proteins: a historic overview. Semin Cancer Biol 2006;16:162- 72.
13. Muslin AJ, Tanner JW, Allen PM, Shaw AS. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 1996;84:889-97. (Pubitemid 26106858)
14. Pozuelo Rubio M, Geraghty KM, Wong BH, Wood NT, Campbell DG, Morrice N, et al. 14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. Biochem J 2004;379:395-408. (Pubitemid 38570113)
15. Jin J, Smith FD, Stark C, Wells CD, Fawcett JP, Kulkarni S, et al. Proteomic, functional, and domain-based analysis of in vivo 14-3-3 binding proteins involved in cytoskeletal regulation and cellular organization. Curr Biol 2004;14:1436-50. (Pubitemid 39123741)
16. van Hemert MJ, Steensma HY, van Heusden GP. 14-3-3 proteins: key regulators of cell division, signalling andapoptosis. Bioessays 2001;23:936-46.
17. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 2006;16:203-13. (Pubitemid 43810260)
18. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3 sigma gene is associated with 50 CpG island hypermethylation in human cancers. Cancer Res 2000;60:4353-7. (Pubitemid 32103610)
19. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 2002;417:871-5.
20. Urano T, Takahashi S, Suzuki T, Fujimura T, Fujita M, Kumagai J, et al. 14-3-3sigma is down-regulated in human prostate cancer. Biochem Biophys Res Commun 2004;319:795-800. (Pubitemid 38739391)
21. Hermeking H. The 14-3-3 cancer connection. Nat Rev Cancer 2003;3: 931-43. (Pubitemid 37500178)
22. Yang HY, Wen YY, Chen CH, Lozano G, Lee MH. 14-3-3 sigma positively regulates p53 and suppresses tumor growth. Mol Cell Biol 2003;23:7096- 107.
23. Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Köttgen E, et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 2000;21:3048-57.
24. Vazquez A, Grochola LF, Bond EE, Levine AJ, Taubert H, Müller TH, et al. Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res 2010;70:172-80.
25. Sedelaar JPM, Isaacs JT. Tissue culture media supplemented with 10%fetal calf serum contains a castrate level of testosterone. Prostate 2009;69:1724-9.
26. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6. (Pubitemid 38391943)
27. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51. (Pubitemid 46026500)
28. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008;68:927-36. (Pubitemid 351206772)
29. Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression pro filing is associated with prostate cancer progression. Cancer Res 2003;63: 3877-82. (Pubitemid 36917897)
30. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9. (Pubitemid 41039166)
31. Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 2004;92:255-64. (Pubitemid 40128246)
32. Morrison DK. The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol 2009;19:16-23.
33. Porter GW, Khuri FR, Fu H. Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol 2006;16:193-202. (Pubitemid 43796125)
34. Yuan Z, Becker EB, Merlo P, Yamada T, DiBacco S, Konishi Y, et al. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science 2008;319:1665- 8.
35. Donovan N, Becker EB, Konishi Y, Bonni A. JNK phosphorylation and activation of BAD couples the stress-activated signaling pathway to the cell death machinery. J Biol Chem 2002;277:40944-9. (Pubitemid 35215682)
36. Sunayama J, Tsuruta F, Masuyama N, Gotoh Y. JNK antagonizes Akt-mediated survival signals by phosphorylating 14-3-3. J Cell Biol 2005;170:295-304. (Pubitemid 41043811)
37. Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y, et al. JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 2004;23:1889-99. (Pubitemid 38649651)
38. Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol 2005;7:278-85. (Pubitemid 40331129)
39. Prasad GL, Valverius EM, McDuffie E, Cooper HL. Complementary DNA cloning of a novel epithelial cell marker protein, HME1 that may be down-regulated in neoplastic mammary cells. Cell Growth Differ 1992;3:507-13.
40. Vercoutter-Edouart AS, Lemoine J, Le Bourhis X, Louis H, Boilly B, NurcombeV, et al. Proteomicanalysis revealsthat14-3-3sigmais downregulated in human breast cancer cells. Cancer Res 2001;61:76-80. (Pubitemid 32095703)
41. Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 2000;97:6049-54. (Pubitemid 30367521)
42. Hong HY, Jeon WK, Bae EJ, Kim ST, Lee HJ, Kim SJ, et al. 14-3-3 sigma and 14-3-3 zeta plays an opposite role in cell growth inhibition mediated by transforming growth factor-beta 1. Mol Cells 2010;29:305-9.
43. Niemantsverdriet M, Wagner K, Visser M, Backendorf C. Cellular functions of 14-3-3 zeta in apoptosis and cell adhesion emphasize its oncogenic character. Oncogene 2008;27:1315-9. (Pubitemid 351294692)
44. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R. Identi fication of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 2005;42:97-108.
45. Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol Res 2004;14:491-9. (Pubitemid 39551562)
46. Ghadimi BM, Grade M, Liersch T, Langer C, Siemer A, Füzesi L, et al. Gain of chromosome 8q23-24 is a predictive marker for lymph node positivity in colorectal cancer. Clin Cancer Res 2003;9:1808-14. (Pubitemid 36554608)
47. Tada K, Oka M, Tangoku A, Hayashi H, Oga A, Sasaki K. Gains of 8q23-qter and 20q and loss of 11q22-qter in esophageal squamous cell carcinoma associated with lymph node metastasis. Cancer 2000;88:268-73. (Pubitemid 30051808)
48. Li Z, Zhao J, Du Y, Park HR, Sun SY, Bernal-Mizrachi L, et al. Downregulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci U S A 2008;105:162-7.
49. Liu MY, Cai S, Espejo A, Bedford MT, Walker CL. 14-3-3 interacts with the tumor suppressor tuberin at Akt phosphorylation site(s). Cancer Res 2002;62:6475-80. (Pubitemid 35364110)
50. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 2008;68:1760-7. (Pubitemid 351416561)
51. Titus MA, Tan JA, Gregory CW, Ford OH, Subramanian RR, Fu H, et al. 14-3-3{eta} amplifies androgen receptor actions in prostate cancer. Clin Cancer Res 2009;15:7571-81.
52. Yang Z, Chang YJ, Miyamoto H, Ni J, Niu Y, Chen Z, et al. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 2007;21:343-58.
53. Haendler B, Schuttke I, Schleuning WD. Androgen receptor signalling: comparative analysis of androgen response elements and implication of heat-shock protein 90 and 14-3-3eta. Mol Cell Endocrinol 2001;173:63-73. (Pubitemid 32149632)
54. Verdoodt B, Benzinger A, Popowicz GM, Holak TA, Hermeking H. Characterization of 14-3-3sigma dimerization determinants: requirement of homodimerization for inhibition of cell proliferation. Cell Cycle 2006;5:2920-26. (Pubitemid 44953948)
55. Quayle SN, Sadar MD. 14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens. Cancer Lett 2007;254:137-45. (Pubitemid 47058813)
56. Neal CL, Yu D. 14-3-3zeta as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets 2010;14:1343-54.